If You Invested in Staar Surg (STAA)

STAAR Surgical Company (NASDAQ: STAA) is a specialized medical device manufacturer focused on ophthalmic surgery. According to company disclosures, STAAR has been dedicated solely to ophthalmic surgery since 1982 and concentrates on implantable intraocular lenses that provide surgical vision correction. The company is described in regulatory and news materials as the global leader in implantable phakic intraocular lenses (IOLs), particularly through its EVO family of Implantable Collamer Lenses (EVO ICL) used for vision correction that can reduce or eliminate the need for glasses or contact lenses.

STAAR designs, develops, manufactures, and markets advanced Implantable Collamer Lenses (ICLs) made from its proprietary biocompatible Collamer material. Company descriptions state that STAAR ICLs are clinically proven to deliver long-term vision correction without removing corneal tissue or the eye’s natural crystalline lens. In addition to phakic ICLs used in refractive surgery, STAAR also manufactures intraocular lenses (IOLs) used in cataract surgery, as reflected in third-party industry classifications and product descriptions. The majority of its sales are generated from ophthalmic surgical products.

STAAR’s EVO ICL product line is described as providing visual freedom through a quick, minimally invasive procedure. Company communications report that STAAR has sold more than 3 million ICLs in over 75 countries, underscoring the global reach of its ophthalmic implant technology. The company is headquartered in Lake Forest, California, and operates research, development, manufacturing, and packaging facilities in California and Switzerland, according to its public communications.

Business focus and product portfolio

Across its disclosures, STAAR emphasizes a focused business model centered on ophthalmic surgical implants. Its primary products are:

• Implantable Collamer Lenses (ICLs) – phakic intraocular lenses used in refractive surgery for vision correction, positioned as an alternative to procedures that remove corneal tissue.
• Intraocular lenses (IOLs) – lenses used in cataract surgery, as described in industry summaries of the company’s operations.
• Delivery systems – systems used to deliver the lenses into the eye, referenced in product descriptions of STAAR’s manufacturing activities.

Public descriptions highlight that STAAR’s ICL technology is based on its proprietary Collamer material, which is characterized as biocompatible. The company’s communications state that its ICLs are clinically proven for safe long-term vision correction, and that EVO ICL technology is intended to be used more extensively worldwide as a vision correction option.

Market role and stock information

STAAR Surgical’s common stock trades on Nasdaq under the ticker symbol STAA, as confirmed in multiple SEC filings. Company and third-party descriptions consistently place STAAR within the surgical and medical instrument manufacturing industry, with a focus on ophthalmic devices. Its positioning as a global leader in implantable phakic IOLs is reiterated across several press releases, particularly in connection with its EVO ICL product family.

Regulatory filings and news reports also show that STAAR has been the subject of significant corporate activity, including an Agreement and Plan of Merger with Alcon Research, LLC announced in August 2025 and later terminated after shareholders did not approve the transaction. Subsequent disclosures state that STAAR remains a standalone, publicly traded company and continues to trade on Nasdaq under the STAA symbol.

Operations and geographic footprint

According to company press releases, STAAR operates research, development, manufacturing, and packaging facilities in California and Switzerland. Its products are reported to have been sold in more than 75 countries, reflecting a broad international customer base for its ophthalmic surgical lenses. While detailed regional breakdowns are not provided in the cited materials, various investor and shareholder communications reference key markets, including regions where refractive surgery and ICL procedures are performed.

Corporate governance and shareholder base

Recent news highlights active engagement between STAAR and several large shareholders. Broadwood Partners, L.P. and its affiliates are repeatedly identified as STAAR’s largest shareholder, owning around 30% of the company’s outstanding common stock in various communications, and later described as holding approximately 31%. Yunqi Capital and other institutional investors are also mentioned as significant shareholders. These parties have been involved in public discussions regarding STAAR’s strategic direction, including opposition to the proposed sale to Alcon and support for STAAR’s prospects as an independent company.

In January 2026, STAAR announced a cooperation agreement with Broadwood under which representatives of Broadwood and Yunqi Capital joined the company’s Board of Directors. The same announcement noted that the size of the Board was expanded and that the company intended to make further announcements regarding its next Chair and CEO. These developments underscore an evolving governance structure influenced by long-term shareholders.

Regulatory reporting and transaction history

STAAR’s SEC filings detail the proposed merger with Alcon, including the original merger agreement, subsequent amendments, go-shop provisions, and multiple adjournments and postponements of the special meeting of stockholders. An 8-K filed in August 2025 describes the agreement under which STAAR would have become a wholly owned subsidiary of Alcon, with its common stock delisted from Nasdaq and deregistered, subject to completion of the merger. Later news reports and company statements confirm that shareholders did not approve the merger and that the agreement was terminated without a termination fee, leaving STAAR as an independent, publicly traded company.

Additional 8-K filings cover topics such as preliminary and final financial results, litigation related to the merger proxy statement, and the establishment of a go-shop period to solicit alternative acquisition proposals. These filings provide insight into STAAR’s transaction processes, shareholder communications, and regulatory obligations as a Nasdaq-listed issuer.

Management and organizational developments

Company filings report that STAAR has made changes in its senior leadership and financial oversight. In June 2025, an 8-K disclosed the appointment of Deborah Andrews as Chief Financial Officer, after she had served as Interim CFO. The same filing noted the creation of a Capital Stewardship Committee of the Board to guide financial strategies, including capital allocation and oversight. Later news reports describe changes to the composition of the Board, including the addition of directors associated with major shareholders and the planned transition of the CEO role.

Summary

Overall, STAAR Surgical Company is characterized in its own communications and regulatory filings as a focused ophthalmic medical device manufacturer that has concentrated on implantable intraocular lenses for vision correction since the early 1980s. Its Nasdaq-listed common stock (symbol STAA), global distribution of ICLs and IOLs, proprietary Collamer-based lens technology, and active shareholder base together define the key elements of the company’s profile for investors and other stakeholders.